View graph of relations
  1. 2018
  2. Published
    Westwood, S., Baird, A. L., Hye, A., Ashton, N. J., Nevado-Holgado, A. J., Anand, S. N., ... Lovestone, S. (2018). Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 10, [409]. DOI: 10.3389/fnagi.2018.00409
  3. Published
    Legdeur, N., Badissi, M., Carter, S. F., de Crom, S., van de Kreeke, A., Vreeswijk, R., ... Visser, P. J. (2018). Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+study. BMC Geriatrics, 18, [289]. DOI: 10.1186/s12877-018-0984-z
  4. Published
    Bergeron, D., Gorno-Tempini, M. L., Rabinovici, G. D., Santos-Santos, M. A., Seeley, W., Miller, B. L., ... Ossenkoppele, R. (2018). Prevalence of amyloid-beta pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 84(5), 729-740. DOI: 10.1002/ana.25333
  5. Published
  6. Published
  7. Published
    Legdeur, N., Heymans, M. W., Comijs, H. C., Huisman, M., Maier, A. B., & Visser, P. J. (2018). Age dependency of risk factors for cognitive decline. BMC Geriatrics, 18. DOI: 10.1186/s12877-018-0876-2
  8. Published
    Konijnenberg, E., Carter, S. F., ten Kate, M., den Braber, A., Tomassen, J., Amadi, C., ... Visser, P. J. (2018). The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Research & Therapy, 10. DOI: 10.1186/s13195-018-0406-7
  9. Published
  10. Published
  11. Published
    ten Kate, M., Sudre, C. H., den Braber, A., Konijnenberg, E., Nivard, M. G., Cardoso, M. J., ... Visser, P. J. (2018). White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging, 66, 40-48. DOI: 10.1016/j.neurobiolaging.2018.02.002
  12. Published
  13. Published
    Tijms, B. M., Willemse, E. A. J., Zwan, M. D., Mulder, S. D., Visser, P. J., van Berckel, B. N. M., ... Teunissen, C. E. (2018). Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta 1-42 Analysis Results. Clinical Chemistry, 64(3), 576-585. DOI: 10.1373/clinchem.2017.281055
  14. Published
  15. Published
  16. Published
  17. 2017
  18. Published
  19. Published
  20. Published
  21. Published
    ten Kate, M., Barkhof, F., Visser, P. J., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Tijms, B. M. (2017). Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimers Research & Therapy, 9, [73]. DOI: 10.1186/s13195-017-0299-x
  22. Published
  23. Published
    Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., ... Winblad, B. (2017). Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, 16(8), 661-676. DOI: 10.1016/S1474-4422(17)30159-X
  24. Published
    Bos, I., Vos, S. J., Froelich, L., Kornhuber, J., Wiltfang, J., Maier, W., ... Alzheimer's Dis Neuroimaging Initi (2017). The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 56, 33-40. DOI: 10.1016/j.neurobiolaging.2017.03.034
  25. Published
    Legdeur, N., Binnekade, T. T., Otten, R. H., Badissi, M., Scheltens, P., Visser, P. J., & Maier, A. B. (2017). Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. Ageing Research Reviews, 36, 42-49. DOI: 10.1016/j.arr.2017.02.006
  26. Published
  27. Published
    Tijms, B. M., Bertens, D., Slot, R. E., Gouw, A. A., Teunissen, C. E., Scheltens, P., ... Visser, P. J. (2017). Low Normal Cerebrospinal Fluid A-beta-42 Levels Predict Clinical Progression in Nondemented Subjects. Annals of Neurology, 81(5), 749-753. DOI: 10.1002/ana.24921
  28. Published
  29. Published
  30. Published
    Herukka, S-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., ... Waldemar, G. (2017). Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & Dementia, 13(3), 285-295. DOI: 10.1016/j.jalz.2016.09.009
  31. Published
    Simonsen, A. H., Herukka, S-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., ... Waldemar, G. (2017). Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's & Dementia, 13(3), 274-284. DOI: 10.1016/j.jalz.2016.09.008
  32. Published
  33. Published
  34. Published
    Miller, A-M., Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., ... Lawlor, B. (2017). Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 60(1), 201-210. DOI: 10.3233/JAD-170502
  35. Published
  36. Published
    van Doorn, L. J. C. V. W., Gispert, J. D., Kuiperij, H. B., Claassen, J. A. H. R., Arighi, A., Baldeiras, I., ... Verbeek, M. M. (2017). Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 56(2), 543-555. DOI: 10.3233/JAD-160668
  37. Published
  38. Published
  39. Published
  40. Published
  41. 2016
  42. Published
  43. Published
    Marchitelli, R., Minati, L., Marizzoni, M., Bosch, B., Bartres-Faz, D., Mueller, B. W., ... Jovicich, J. (2016). Test-Retest Reliability of the Default Mode Network in a Multi-Centric fMRI Study of Healthy Elderly: Effects of Data-Driven Physiological Noise Correction Techniques. Human Brain Mapping, 37(6), 2114-2132. DOI: 10.1002/hbm.23157
  44. Published
    ten Kate, M., Sanz-Arigita, E. J., Tijms, B. M., Wink, A. M., Clerigue, M., Garcia-Sebastian, M., ... Barkhof, F. (2016). Impact of APOE-epsilon 4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, 38, 14-20. DOI: 10.1016/j.neurobiolaging.2015.10.018
  45. Published
    Jack, C. R. . J., Knopman, D. S., Chetelat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., ... Vos, S. J. B. (2016). Suspected non-Alzheimer disease pathophysiology - concept and controversy. Nature Reviews Neurology, 12(2), 117-124. DOI: 10.1038/nrneurol.2015.251
  46. Published
    Zwan, M. D., Rinne, J. O., Hasselbalch, S. G., Nordberg, A., Lleo, A., Herukka, S-K., ... Visser, P. J. (2016). Use of amyloid-PET to determine cutpoints for CSF markers A multicenter study. Neurology, 86(1), 50-58. DOI: 10.1212/WNL.0000000000002081
  47. Published
    Jovicich, J., Minati, L., Marizzoni, M., Marchitelli, R., Sala-Llonch, R., Bartres-Faz, D., ... Frisoni, G. B. (2016). Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. Neuroimage, 124, 442-454. DOI: 10.1016/j.neuroimage.2015.07.010
  48. Published
    Tijms, B. M., ten Kate, M., Wink, A. M., Visser, P. J., Ecay, M., Clerigue, M., ... Barkhof, F. (2016). Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 37, 154-160. DOI: 10.1016/j.neurobiolaging.2015.10.015
  49. Published
  50. Published
    Tsolaki, M., Papaliagkas, V., Frisoni, G., Jones, R., Touchon, J., Spiru, L., ... Visser, P. J. (2016). MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. Current Alzheimer Research, 13(12), 1407-1413. DOI: 10.2174/1567205013666160603002704
  51. 2015
  52. Published
    Reijs, B. L. R., Teunissen, C. E., Goncharenko, N., Betsou, F., Blennow, K., Baldeiras, I., ... Visser, P. J. (2015). The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases. Frontiers in Neurology, 6, [216]. DOI: 10.3389/fneur.2015.00216
  53. Published
  54. Published
    Tang, E. Y. H., Harrison, S. L., Errington, L., Gordon, M. F., Visser, P. J., Novak, G., ... Stephan, B. C. M. (2015). Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. PLOS ONE, 10(9), [e0136181]. DOI: 10.1371/journal.pone.0136181
Previous 1 2 3 Next